Aditya Birla SL Pharma & Healthcare Fund
Ticker: mf13175
Decent
68/100
☆ Add to Watchlist
More Options
N
Nippon India Nifty G-Sec Jun 2036 Maturity Index Fund
The Nippon India Nifty G-Sec Jun 2036 Maturity Index Fund presents a decent investment opportunity for conservative investors seeking stability in fixed income, though growth potential is limited.
View details
E
Edelweiss Equity Savings Fund
Edelweiss Equity Savings Fund shows decent potential with consistent growth and manageable risks, but investors should remain cautious about valuation and execution risks.
View details
I
ITI Large & Mid Cap Fund
The fund shows potential but is currently facing several risks that could impact future performance.
View details
U
UTI Innovation Fund
The UTI Innovation Fund shows potential for growth in innovative sectors, but faces challenges in profitability and valuation metrics. Caution is advised for investors.
View details
M
Motilal Oswal Digital India Fund
The fund shows potential with a decent score, but caution is advised due to execution risks and market sentiment.
View details
L
LIC MF Overnight Fund
The LIC MF Overnight Fund is a stable investment option with moderate growth potential, but lacks significant competitive advantages.
View details
L
LIC MF Balanced Advantage Fund
The LIC MF Balanced Advantage Fund shows potential for moderate growth, but investors should be cautious due to volatility in profits and execution risks.
View details
L
LIC MF Manufacturing Fund
The LIC MF Manufacturing Fund shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised.
View details
D
DSP NIFTY 50 Index Fund
The DSP NIFTY 50 Index Fund is a decent investment option with stable growth potential, but investors should be cautious of valuation and governance aspects.
View details
H
HSBC Low Duration Fund
The HSBC Low Duration Fund presents several risks with limited growth potential and average profitability metrics, making it a risky investment at this time.
View details
B
Baroda BNP Paribas Conservative Hybrid Fund
The fund shows potential with a decent score, but investors should be cautious of execution risks and liquidity issues.
View details
U
UTI Banking & PSU Fund
The UTI Banking & PSU Fund shows decent potential but is facing challenges that could impact future performance. Investors should be cautious.
View details
M
Mahindra Manulife Manufacturing Fund
The fund shows potential with solid growth and profitability metrics, but faces challenges in governance and market sentiment.
View details
A
Aditya Birla SL Special Opp Fund
The fund shows decent potential with consistent growth and profitability metrics, but caution is advised due to valuation concerns and execution risks.
View details
I
Invesco India Short Duration Fund
The fund shows potential with a decent score, but there are areas of concern that need to be monitored closely.
View details
J
JM Aggressive Hybrid Fund
The JM Aggressive Hybrid Fund shows potential but faces several challenges that could impact future performance. Investors should approach with caution.
View details
Business Overview
The Aditya Birla SL Pharma & Healthcare Fund is a focused mutual fund that invests primarily in the pharmaceutical and healthcare sectors. It is designed for investors seeking long-term capital appreciation through exposure to high-growth companies in these critical industries. This fund is ideal for those looking to diversify their portfolio while tapping into the potential of India's booming healthcare market.
- Focuses on pharmaceutical and healthcare sectors
- Aims for long-term capital appreciation
- Ideal for risk-tolerant investors
- Diversifies investment portfolio
- Taps into India's growing healthcare market
Investment Thesis
Aditya Birla SL Pharma & Healthcare Fund stands out due to its strong promoter group, which ensures credibility and stability. The fund is well-positioned to capitalize on the growing digital services in healthcare, offering a significant growth runway. Additionally, its attractive valuation compared to peers makes it an appealing investment opportunity for retail investors.
- Strong backing from the Aditya Birla Group enhances trust and stability.
- Significant growth potential in digital healthcare services.
- Attractive valuation compared to industry peers, offering potential upside.
- Diversified portfolio reduces risk while targeting high-growth sectors.
- Experienced management team with a proven track record in fund performance.
Opportunity vs Risk
Opportunities
- Strong growth in healthcare sector
- Increasing demand for pharmaceuticals
- Government support for healthcare initiatives
- Rising awareness of health and wellness
Risks ⚠️
- Regulatory changes affecting pricing
- Intense competition in the market
- Economic downturn impact on spending
- Supply chain disruptions
Peer Perspective
Aditya Birla SL Pharma & Healthcare Fund trades at a slight premium compared to peers like Nippon India Pharma Fund and SBI Pharma Fund. A sustained improvement in margin stability could trigger a rerating.
???? Future Outlook
Aditya Birla SL Pharma & Healthcare Fund is well-positioned for growth, driven by increasing healthcare demand. However, successful execution and effective cost management will be crucial to fully capitalize on emerging opportunities.
AI FAQs for Retail Users
- Q: What is Aditya Birla SL Pharma & Healthcare Fund?A: It is a mutual fund focusing on investments in the pharmaceutical and healthcare sectors.
- Q: Who should invest in this fund?A: Investors looking for exposure to the healthcare industry and willing to accept market risks.
- Q: What are the risks associated with this fund?A: Market volatility, sector-specific risks, and potential regulatory changes can impact fund performance.
- Q: How can I invest in this fund?A: Invest through mutual fund platforms, banks, or directly via the fund's website.
- Q: What is the investment horizon for this fund?A: A long-term investment horizon is generally recommended to potentially benefit from sector growth.
📊 Stock Investment Checklist (100 Points)
Aditya Birla SL Pharma & Healthcare Fund • Updated: 2025-09-29 10:36:30
-
10BusinessHighThe sector is growing with increasing healthcare demands.
-
10GrowthHighConsistent revenue growth but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is inconsistent.
-
8ValuationHighValuation metrics are slightly above peers.
-
7BalanceHighModerate debt levels with reasonable liquidity.
-
6GovernanceGoodPromoter holding is stable, but some pledging exists.
-
5DriversGoodGrowth catalysts are present but execution risks are high.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The fund shows potential in a growing sector but faces challenges in profitability and execution risks.